The single mediator approach to asthma therapy: is it so unreasonable

Lynette Fernandes, Roy Goldie

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Asthma involves a complex syndrome of respiratory pathologies that ultimately results in bronchial obstruction and reduced lung ventilatory capacity. Inflammation of the respiratory tract underlies this disease and can be linked to the production and release of multiple mediators of bronchoconstriction and airway wall restructuring and obstruction. Disease triggers vary between patients and include allergens, exercise, inhaled irritants and virus infections. Disease severity can also be highly variable from patient to patient. All of this indicates a heterogeneous disease phenomenon. Bronchodilator drugs that induce rapid symptom relief are just one component of conventional asthma therapy. The use of controller agents, such as anti-inflammatory glucocorticoids, constitutes the other important treatment option. The question is whether a key mediator is released in asthma that can be targeted by either single or multiple therapeutic agents to halt or reverse this complex mix of disease processes.
Original languageEnglish
Pages (from-to)251-256
JournalCurrent Opinion in Pharmacology
Volume3
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Asthma
Lung Volume Measurements
Respiratory Tract Diseases
Bronchoconstriction
Irritants
Bronchodilator Agents
Virus Diseases
Therapeutics
Allergens
Glucocorticoids
Anti-Inflammatory Agents
Exercise
Pathology
Inflammation
Pharmaceutical Preparations

Cite this

@article{d99a08d65e2d47cba8ed843e55676d02,
title = "The single mediator approach to asthma therapy: is it so unreasonable",
abstract = "Asthma involves a complex syndrome of respiratory pathologies that ultimately results in bronchial obstruction and reduced lung ventilatory capacity. Inflammation of the respiratory tract underlies this disease and can be linked to the production and release of multiple mediators of bronchoconstriction and airway wall restructuring and obstruction. Disease triggers vary between patients and include allergens, exercise, inhaled irritants and virus infections. Disease severity can also be highly variable from patient to patient. All of this indicates a heterogeneous disease phenomenon. Bronchodilator drugs that induce rapid symptom relief are just one component of conventional asthma therapy. The use of controller agents, such as anti-inflammatory glucocorticoids, constitutes the other important treatment option. The question is whether a key mediator is released in asthma that can be targeted by either single or multiple therapeutic agents to halt or reverse this complex mix of disease processes.",
author = "Lynette Fernandes and Roy Goldie",
year = "2003",
doi = "10.1016/S1471-4892(03)00042-0",
language = "English",
volume = "3",
pages = "251--256",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier",
number = "3",

}

The single mediator approach to asthma therapy: is it so unreasonable. / Fernandes, Lynette; Goldie, Roy.

In: Current Opinion in Pharmacology, Vol. 3, No. 3, 2003, p. 251-256.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The single mediator approach to asthma therapy: is it so unreasonable

AU - Fernandes, Lynette

AU - Goldie, Roy

PY - 2003

Y1 - 2003

N2 - Asthma involves a complex syndrome of respiratory pathologies that ultimately results in bronchial obstruction and reduced lung ventilatory capacity. Inflammation of the respiratory tract underlies this disease and can be linked to the production and release of multiple mediators of bronchoconstriction and airway wall restructuring and obstruction. Disease triggers vary between patients and include allergens, exercise, inhaled irritants and virus infections. Disease severity can also be highly variable from patient to patient. All of this indicates a heterogeneous disease phenomenon. Bronchodilator drugs that induce rapid symptom relief are just one component of conventional asthma therapy. The use of controller agents, such as anti-inflammatory glucocorticoids, constitutes the other important treatment option. The question is whether a key mediator is released in asthma that can be targeted by either single or multiple therapeutic agents to halt or reverse this complex mix of disease processes.

AB - Asthma involves a complex syndrome of respiratory pathologies that ultimately results in bronchial obstruction and reduced lung ventilatory capacity. Inflammation of the respiratory tract underlies this disease and can be linked to the production and release of multiple mediators of bronchoconstriction and airway wall restructuring and obstruction. Disease triggers vary between patients and include allergens, exercise, inhaled irritants and virus infections. Disease severity can also be highly variable from patient to patient. All of this indicates a heterogeneous disease phenomenon. Bronchodilator drugs that induce rapid symptom relief are just one component of conventional asthma therapy. The use of controller agents, such as anti-inflammatory glucocorticoids, constitutes the other important treatment option. The question is whether a key mediator is released in asthma that can be targeted by either single or multiple therapeutic agents to halt or reverse this complex mix of disease processes.

U2 - 10.1016/S1471-4892(03)00042-0

DO - 10.1016/S1471-4892(03)00042-0

M3 - Review article

VL - 3

SP - 251

EP - 256

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 3

ER -